Rhenman & Partners Asset Management Ab has filed its 13F form on February 13, 2025 for Q4 2024 where it was disclosed a total value porftolio of $959 Million distributed in 92 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Boston Scientific Corp with a value of $39.7M, Eli Lilly & CO with a value of $35.1M, Procept Bio Robotics Corp with a value of $33.8M, Intuitive Surgical Inc with a value of $33.4M, and Regeneron Pharmaceuticals, Inc. with a value of $31M.

Examining the 13F form we can see an decrease of $242M in the current position value, from $1.2B to 959M.

Rhenman & Partners Asset Management Ab is based out at Stockholm, V7

Below you can find more details about Rhenman & Partners Asset Management Ab portfolio as well as his latest detailed transactions.

Portfolio value $959 Million
Healthcare: $957 Million
Basic Materials: $1.3 Million

Stock Holdings Table Companies Only

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History

Summary

  • Portfolio
  • No. of Stocks 92
  • Current Value $959 Million
  • Prior Value $1.2 Billion
  • Filing
  • Period Q4 2024
  • Filing Date February 13, 2025
  • Form Type 13F-HR
  • Activity in Q4 2024
  • New Purchases 2 stocks
  • Additional Purchases 29 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 54 stocks
Track This Portfolio

Track Rhenman & Partners Asset Management Ab Portfolio

Follow Rhenman & Partners Asset Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.